ANIP
ANI Pharmaceuticals Inc
71.90$
+0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 55.9% | 57.5% | 59.1% | 60.3% | 40.5% | 41.1% | 41.5% | 44.9% | 49.6% | 52.3% | 52.5% | 55.2% | |
| 21.7% | 24.4% | 25.0% | 26.1% | 11.3% | 11.3% | 11.6% | 16.2% | 18.6% | 19.8% | 21.9% | 24.1% | |
| 21.7% | 24.4% | 26.1% | 26.8% | 11.9% | 11.8% | 12.0% | 16.6% | 18.6% | 19.8% | 21.9% | 25.2% | |
| 20.1% | 17.9% | 18.9% | 18.0% | 15.3% | 17.3% | 17.0% | 16.8% | 17.9% | 19.5% | 18.0% | 18.4% | |
| 12.0% | 12.3% | 12.4% | 13.6% | 11.5% | 10.7% | 10.6% | 10.3% | 10.4% | 9.9% | 10.1% | 9.6% | |
| 3.2% | 3.1% | 3.1% | 3.1% | 4.7% | 4.7% | 4.7% | 4.5% | 4.4% | 4.3% | 4.4% | 4.2% | |
| 24.7% | 23.1% | 21.4% | 19.9% | 44.3% | 42.2% | 41.7% | 38.7% | 35.5% | 33.3% | 32.9% | 30.1% | |
| 48.9% | 52.2% | 50.6% | 47.8% | 66.5% | 66.6% | 65.7% | 65.6% | 64.1% | 62.5% | 60.5% | 60.0% | |
| 15.1% | 16.1% | 15.0% | 15.2% | 14.8% | 15.1% | 15.6% | 17.6% | 19.2% | 19.3% | 16.8% | 19.0% | |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.6% | 0.7% | 0.9% | 1.0% | 1.1% | 1.2% | 1.4% | 1.4% | |
| 3.8% | 4.1% | 5.4% | 5.3% | 4.7% | 3.6% | 4.1% | 4.1% | 5.0% | 4.3% | 4.9% | 4.9% | |
| 32.0% | 31.5% | 31.1% | 30.9% | 48.0% | 47.9% | 47.3% | 45.3% | 43.0% | 41.6% | 41.8% | 39.4% | |
| 51.1% | 47.8% | 49.4% | 52.2% | 33.5% | 33.4% | 34.3% | 34.4% | 35.9% | 37.5% | 39.5% | 40.0% | |
| -9.1% | -8.9% | -6.8% | -7.1% | -7.0% | -7.8% | -6.6% | -5.7% | -3.6% | -1.6% | 0.4% | 2.1% | |
| 2.1% | 2.1% | 2.1% | 2.1% | 1.5% | 1.5% | 1.6% | 1.5% | 1.5% | 1.5% | 1.5% | 1.5% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.